Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia

Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia

Acute myelogenous leukemia (AML) is a heterogeneous disease and often relapses after standard chemotherapy. Recently, the neddylation (NEDD8) and the mammalian target of rapamycin (mTOR) signaling pathways have emerged as promising pharmaceutical targets for AML therapy. However, the interaction of...

Full description

Bibliographic Details
Main Authors:	Naxin Guo, Mitra Azadniv, Myra Coppage, Mary Nemer, Jason Mendler, Michael Becker, Jane Liesveld
Format:	Article
Language:	English
Published:	Elsevier 2019-04-01
Series:	Translational Oncology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523318303863

Similar Items

Targeting Myelogenous Leukemia Stem Cells: Role of the Circulation.
by: Jane eLiesveld
Published: (2012-08-01)

Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia
by: Qiu-yu Lai, et al.
Published: (2019-07-01)

Hydroxycitric Acid Inhibits Chronic Myelogenous Leukemia Growth through Activation of AMPK and mTOR Pathway
by: Doriana Verrelli, et al.
Published: (2022-06-01)

Camptothecin Inhibits Neddylation to Activate the Protective Autophagy Through NF-κB/AMPK/mTOR/ULK1 Axis in Human Esophageal Cancer Cells
by: Yongqing Heng, et al.
Published: (2021-04-01)

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
by: Xin P, et al.
Published: (2017-04-01)

Targeting mTOR in Acute Lymphoblastic Leukemia
by: Carolina Simioni, et al.
Published: (2019-02-01)

AAA + ATPase Thorase inhibits mTOR signaling through the disassembly of the mTOR complex 1
by: George K. E. Umanah, et al.
Published: (2022-08-01)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
by: Victor H. Villar, et al.
Published: (2017-05-01)

Apoptosis resistance in chronic myelogenous leukemia
by: Fabíola Attié de Castro, et al.
Published: (2005-09-01)

Bosutinib in the management of chronic myelogenous leukemia
by: Keller-von Amsberg G, et al.
Published: (2013-05-01)

Molecular basis of Acute Myelogenous Leukemia
by: Eduardo M. Rego
Published: (2002-01-01)

The effects of mTOR inhibition in ischemic stroke
by: Schneider, AM
Published: (2022)

mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death.
by: Rana Baraz, et al.
Published: (2014-01-01)

Occurrence of chronic lymphocytic leukemia in patients with chronic myelogenous leukemia
by: Pritish K Bhattacharyya
Published: (2013-01-01)

Analysis of telomere length in chronic myelogenous leukemia.
by: Boultwood, J, et al.
Published: (1997)

Analysis or telomere length in chronic myelogenous leukemia
by: Fidler, C, et al.
Published: (1998)

A mathematical model of chronic myelogenous leukemia
by: Neiman, B
Published: (2000)

Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia
by: Gopalarethinam Janani, et al.
Published: (2023-09-01)

Green crystals of death in chronic myelogenous leukemia
by: Mohammad Esmaeil Khedmati, et al.
Published: (2022-01-01)

Applications of Microarray Technology to Acute Myelogenous Leukemia
by: Rashmi S. Goswami, et al.
Published: (2009-01-01)

Wnt Signaling Pathway and Chronic Myelogenous Leukemia
by: HOU Yan, et al.
Published: (2019-02-01)

Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
by: Harnicar S, et al.
Published: (2014-08-01)

Applications of Microarray Technology to Acute Myelogenous Leukemia
by: Rashmi S. Goswami, et al.
Published: (2009-01-01)

Activated mTOR signaling pathway in myofibers with inherited metabolic defect might be an evidence for mTOR inhibition therapies
by: Jing-Wei Lyu, et al.
Published: (2019-04-01)

Resistance mechanisms to mTOR inhibition in renal cancer
by: Earwaker, P
Published: (2015)

Medical Aspects of mTOR Inhibition in Kidney Transplantation
by: Elena Cuadrado-Payán, et al.
Published: (2022-07-01)

Frentizole derivatives with mTOR inhibiting and senomorphic properties
by: Zofia Chrienova, et al.
Published: (2023-11-01)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
by: Yim K-L
Published: (2012-07-01)

Exploring mTOR inhibition as treatment for mitochondrial disease
by: Abigail Sage‐Schwaede, et al.
Published: (2019-09-01)

Inhibition of NF-κB Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics
by: Håkon Reikvam
Published: (2020-07-01)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
by: Luise Spormann, et al.
Published: (2020-07-01)

MLN4924: additional activities beyond neddylation inhibition
by: Qiyin Zhou, et al.
Published: (2019-09-01)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
by: Zhilin Zou, et al.
Published: (2020-03-01)

Chronic myelogenous leukemia: molecular monitoring in clinical practice
by: N. R. Ryabchikova, et al.
Published: (2014-07-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Chronic myelogenous leukemia: molecular monitoring in clinical practice
by: N. R. Ryabchikova, et al.
Published: (2014-07-01)

Nephrotic syndrome as the first manifestation of Acute Myelogenous leukemia
by: Mohammadali Mashhadi
Published: (2010-07-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Evaluation of Chemotherapy Toxicity in Acute Lymphoblastic and Myelogenous Leukemia
by: Ardeshir Ghavamzadeh, et al.
Published: (2012-04-01)

Evaluation of Chemotherapy Toxicity in Acute Lymphoblastic and Myelogenous Leukemia
by: Taher Entezari-Maleki, et al.
Published: (2012-06-01)